Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Amylyx Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2022
FY2023
FY2024
FY2025
Revenue
0.29
22.2
381
87.4
0
Cost of revenue
2.99
25.4
5.95
0
Gross profit
19.2
355
81.4
0
Research and development
44
93.5
128
104
90.4
Selling, general and administrative
38.9
127
188
114
62.9
Operating income
-82.7
-201
38.8
-315
-153
Interest income
0.04
4.29
16.2
13.8
9.3
Other non-operating income
-5.24
3.74
15.5
12.6
8.6
Pre-tax income
-87.9
-198
54.3
-302
-145
Income tax
0.77
5.03
-0.39
0.05
Net income
-87.9
-198
49.3
-302
-145
EBITDA
-82.6
-201
39.9
-314
-153
EPS, basic
-13.35
-3.39
0.73
-4.43
-1.53
EPS, diluted
-13.35
-3.39
0.70
-4.43
-1.53
Shares, basic (weighted)
6.59
58.5
67.2
68.1
94.6
Shares, diluted (weighted)
6.59
58.5
70
68.1
94.6
Balance sheet
FY2022
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
50.2
62.5
170
77.4
227
Short-term investments
45.9
284
201
99.1
90.3
Receivables
15.3
40.1
0.45
0.09
Inventory
9.77
38.3
Other current assets
5.39
10.1
14.9
12.5
6.69
Total current assets
105
382
465
189
324
Property, plant and equipment
0.47
2.61
2.69
0.96
0.31
Lease right-of-use assets
5.52
3.73
1.77
5.18
Other non-current assets
0.47
0.7
0.02
2.5
Total assets
106
391
517
194
333
Accounts payable
4.37
6.26
22.1
2.94
3.52
Accrued liabilities
4.28
38.3
57.7
23.9
17.9
Total current liabilities
17.4
46.6
82
28.4
22.7
Lease liabilities
4.24
1.98
0.46
4.7
Total liabilities
17.4
50.8
84
28.9
27.4
Paid-in capital
4.67
695
738
772
1,056
Retained earnings
-156
-354
-305
-607
-751
Other comprehensive income
0.01
-0.09
0.2
-0.09
0.4
Shareholders' equity
-151
341
433
165
305
Total equity
-151
341
433
165
305
Total liabilities and equity
106
391
517
194
333
Shares outstanding
7.02
66.5
67.7
68.6
110
Cash flow statement
FY2022
FY2022
FY2023
FY2024
FY2025
Net income
-87.9
-198
49.3
-302
-145
Depreciation and amortization
0.05
0.49
1.09
0.9
0.53
Stock-based compensation
3.14
21.7
37.2
33
27.6
Change in receivables
-15.3
-24.7
39.6
0.36
Change in inventory
-9.77
-73.1
-9.25
Change in payables
0.67
1.85
15.9
-19.1
0.58
Cash from operations
-74.8
-180
11.9
-168
-123
Capital expenditures
-0.35
-2.53
-1.24
-0.16
-0.14
Purchases of investments
-49.1
-416
-301
-232
-232
Sales and maturities of investments
3
179
394
344
246
Cash from investing
-46.4
-239
92.1
75.7
14
Stock issued
0.34
2.19
6.99
Cash from financing
159
432
3.54
0.35
257
Exchange rate effect
0.01
-0.07
0.16
-0.44
1.07
Net change in cash
37.3
12.9
108
-92.1
149
Free cash flow
-75.2
-182
10.7
-168
-123
Income taxes paid
0.03
6.39
0.24
-1.04
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $29.49 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-63.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-57.5%
Net income / average total assets.
Return on invested capital (ROIC)
-67.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-100.0%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
-100.0%
Gross profit vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
85.3%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-3.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
71.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-5.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
38.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
17.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
12.1x
Current assets / current liabilities.
Quick ratio
11.9x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
11.9x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$1.14
Cash from operations / diluted weighted shares.
Book value per share
$2.15
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
13.7x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
13.7x
Market cap / tangible book value, when positive.
Earnings yield
-4.6%
Net income / market cap (the inverse of P/E).
What was Amylyx Pharmaceuticals, Inc.'s revenue in fiscal 2025?
Amylyx Pharmaceuticals, Inc. reported revenue of $0.0 for fiscal 2025, 100% lower than the year before.
Was Amylyx Pharmaceuticals, Inc. profitable in fiscal 2025?
No. It reported a net loss of $144.7M.
How much free cash flow did Amylyx Pharmaceuticals, Inc. generate in fiscal 2025?
Cash from operations of $123.3M minus capital expenditures of $138.0K left free cash flow of -$123.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.